Treatment for glioblastoma (GBM)
Intended for US audiences only.

Small.
Light.
Designed for
everyday life.

Hover over each blue
illustration to learn more

Tap each blue illustration to learn more

Transducer Arrays

Transducer Arrays

Electric field generator

Connection cable and box

Easy-access sleeve bag

Convertible, 5-in-1 bag

Optune is small and light weighing just 2.7 pounds. This makes Optune wearable and portable, so continuous treatment with Optune can be received almost anywhere.

The recommendation to turn Optune on at least 75% of the time (18 hours per day) gives you the flexibility to decide which times of the day are best for you. You can customize your Optune treatment plan by taking breaks during the day.

Four sterile, single-use transducer arrays are connected to the electric field generator to deliver therapy. Transducer arrays should be changed at least 2 times per week (one set of arrays should not be worn for more than 4 days at a time).

Four sterile, single-use transducer arrays are connected to the electric field generator to deliver therapy. Transducer arrays should be changed at least 2 times per week (one set of arrays should not be worn for more than 4 days at a time).

The portable field generator should be carried with you to deliver Tumor Treating Fields (TTFields) as you go about your day.

Black and white color-coded sockets on the cable box help ensure that transducer array connectors are properly connected.

Openings conveniently located at the top and bottom make it easy to reach device controls.

The convertible, 5-in-1 bag can be worn 5 different ways and has additional battery storage, making it ideal for on-the-go use.

The system offers features designed to enhance carrying comfort and usability:

  • Easy-grip texture allows for simple handling
  • Battery indicator displays power and alerts you when it’s time to change the battery
  • Light-detecting sensor auto-dims the device and the charger in the dark

Other components include:

  • Portable batteries: 4 batteries are provided with each kit; each battery lasts for 2 to 3 hours
  • Charger for portable batteries: Batteries will need to be recharged for 2 to 4 hours. The batteries can be charged and used many times over the course of 6 to 9 months
  • Plug-in power supply and power cords: “No-Stop Swap” enables you to swap batteries or power source without disrupting delivery of TTFields

Applying transducer arrays

Optune delivers therapy through 4 adhesive patches, called tranducer arrays. These arrays are applied to your scalp. They are powered through the connection cable and box, which is powered by the battery. If you or your loved one is starting treatment with Optune, applying transducer arrays will soon become a part of your routine. With the help of a caregiver, your head will be shaved and arrays changed at least 2 times per week (one set of arrays should not be worn for more than 4 days at a time).

Optune offers flexibility to help you incorporate treatment into your daily life

A large clinical study demonstrated that people who used Optune at least 75% of the time (18 hours per day) lived longer. This gives you the flexibility to decide which times of day are best for you. You can customize your Optune treatment plan by taking breaks during the day.

References:
  1. Optune Fact Sheet. https://www.novocure.com/wp-content/uploads/2016/08/OPT-539_Optune-Fact-Sheet_062016-2.pdf. Novocure 2017.
  2. Optune Patient Information and Operation Manual. Novocure 2017.
  3. Stupp R, Taillibert S, Kanner A, et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA Oncology. 2017­318(23):2306−2316.

What is Optune approved to treat?

Optune is indicated to treat a type of brain cancer called glioblastoma multiforme (GBM) in adult patients 22 years of age or older.

Newly diagnosed GBM

If you have newly diagnosed GBM, Optune is used together with a chemotherapy called temozolomide (TMZ) if:

Recurrent GBM

If your tumor has come back, Optune can be used alone as an alternative to standard medical therapy if:

What is the NovoTTF-100L System approved to treat?

The NovoTTF-100L System is a wearable, portable, FDA-approved device indicated for the treatment of adult patients, with unresectable, locally advanced or metastatic, malignant pleural mesothelioma (MPM) to be used together with standard chemotherapy (pemetrexed and platinum-based chemotherapy).

Who should not use Optune for GBM or the NovoTTF-100L System for MPM?

Optune for GBM and the NovoTTF-100L System for MPM are not for everyone. Talk to your doctor if you have:

Do not use Optune for GBM or the NovoTTF-100L System for MPM if you are pregnant or are planning to become pregnant. It is not known if Optune/the NovoTTF-100L System is safe or effective during pregnancy.

What should I know before using Optune for GBM or the NovoTTF-100L System for MPM?

Optune and the NovoTTF-100L System should only be used after receiving training from qualified personnel, such as your doctor, a nurse, or other medical staff who have completed a training course given by Novocure®, the maker of Optune and the NovoTTF-100L System.

What are the possible side effects of Optune for GBM and the NovoTTF-100L System for MPM?

The most common side effects of Optune when used together with chemotherapy for GBM (temozolomide or TMZ) were low blood platelet count, nausea, constipation, vomiting, tiredness, scalp irritation from the device, headache, seizure, and depression.

The most common side effects when using Optune alone for GBM were scalp irritation (redness and itchiness) and headache. Other side effects were malaise, muscle twitching, fall and skin ulcers.

The most common side effects of the NovoTTF-100L System when used together with chemotherapy for MPM (pemetrexed and platinum-based chemotherapy) were low blood platelet count, constipation, nausea, tiredness, chest pain, fatigue, skin irritation from device use, itchy skin, and cough.

Other potential adverse effects associated with the use of the NovoTTF-100L System include: treatment related skin irritation, allergic reaction to the plaster or to the gel, electrode overheating leading to pain and/or local skin burns, infections at sites of electrode contact with the skin, local warmth and tingling sensation beneath the electrodes, muscle twitching, medical site reaction and skin breakdown/skin ulcer.

Talk to your doctor if you have any of these side effects or questions.

Caution: Federal law restricts the NovoTTF-100L System to sale by or on the order of a physician. Humanitarian Device. Authorized by Federal Law for use in the treatment of adult patients with unresectable, locally advanced or metastatic, malignant pleural mesothelioma concurrently with pemetrexed and platinum-based chemotherapy. The effectiveness of this device for this use has not been demonstrated.


Please click here to see the Optune Instructions for Use (IFU) for complete information regarding the device's indications, contraindications, warnings, and precautions.

Please click here to see the NovoTTF-100L IFU for complete information regarding the device's indications, contraindications, warnings, and precautions.


On this site, patient and healthcare professional videos as well as all images labeled as Optune users, caregivers, or healthcare professionals depict actual patients, caregivers, and healthcare professionals. All other depictions of patients and caregivers are actor portrayals. Patient images reflect the health status of the patients at the time each photo was taken.

What is Optune approved to treat?

Optune is indicated to treat a type of brain cancer called glioblastoma multiforme (GBM) in adult patients 22 years of age or older.